Sorafenib reveals efficacy in sequential treatment of metastatic renal cell cancer

References

• Vickers MM, Choueiri TK, Percy A et al. Failure of initial VEGF-targeted therapy in metastatic renal cell carcinoma (mRCC): what next? Presented at: American Society of Clinical Oncology Annual Meeting. Orlando, FL, USA, 29 May–2 June 2009.
   Google Scholar
• Bodrogi I. [Effect of angiogenesis inhibitors on renal cell carcinoma]. Magy. Onkol.51(2), 145–153 (2007).
   PubMedGoogle Scholar
• Merseburger AS, Kuczyk MA. [Value of targeted therapies for renal cell cancer]. Urologe A47(10), 1303–1310 (2008).
   PubMedGoogle Scholar
• Kruck S, Merseburger AS, Gakis G, Kramer MW, Stenzl A, Kuczyk MA. An update on the medical therapy of advanced metastatic renal cell carcinoma. Scand. J. Urol. Nephrol.42(6), 501–506 (2008).
   PubMed Web of Science ®Google Scholar
• Bastien L, Culine S, Paule B, Ledbai S, Patard JJ, de la Taille A. Targeted therapies in metastatic renal cancer in 2009. BJU Int.103(10), 1334–1342 (2009).
   PubMed Web of Science ®Google Scholar
• Mills EJ, Rachlis B, O’Regan C, Thabane L, Perri D. Metastatic renal cell cancer treatments: an indirect comparison meta-analysis. BMC Cancer9, 34 (2009).
   PubMed Web of Science ®Google Scholar
• Tamaskar I, Garcia JA, Elson P et al. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J. Urol.179(1), 81–86 (2008).
   PubMed Web of Science ®Google Scholar
• Dudek AZ, Zolnierek J, Dham A, Lindgren BR, Szczylik C. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer115(1), 61–67 (2009).
   PubMed Web of Science ®Google Scholar
• Eichelberg C, Heuer R, Chun FK et al. Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis. Eur. Urol.54(6), 1373–1378 (2008).
   PubMed Web of Science ®Google Scholar
• Patard JJ, Pouessel D, Culine S. New therapies in renal cell carcinoma. Curr. Opin. Support. Palliat. Care1(3), 174–179 (2007).
   PubMedGoogle Scholar
• Patard JJ, Pouessel D, Bensalah K, Culine S. Targeted therapy in renal cell carcinoma. World J. Urol.26(2), 135–140 (2008).
   PubMedGoogle Scholar
• Lainakis G, Bamias A. Targeting angiogenesis in renal cell carcinoma. Curr. Cancer Drug Targets8(5), 349–358 (2008).
   PubMed Web of Science ®Google Scholar
• Strumberg D, Richly H, Hilger RA et al. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J. Clin. Oncol.23(5), 965–972 (2005).
   PubMed Web of Science ®Google Scholar
• Strumberg D, Seeber S. Raf kinase inhibitors in oncology. Onkologie28(2), 101–107 (2005).
   PubMedGoogle Scholar
• Cheng AL, Kang YK, Chen Z et al. Efficacy and safety of sorafenib in patients in the Asia–Pacific region with advanced hepatocellular carcinoma: a Phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol.10(1), 25–34 (2009).
   PubMed Web of Science ®Google Scholar
• Dahut WL, Scripture C, Posadas E et al. A Phase II clinical trial of sorafenib in androgen-independent prostate cancer. Clin. Cancer Res.14(1), 209–214 (2008).
   PubMed Web of Science ®Google Scholar
• Gupta-Abramson V, Troxel AB, Nellore A et al. Phase II trial of sorafenib in advanced thyroid cancer. J. Clin. Oncol.26(29), 4714–4719 (2008).
   PubMed Web of Science ®Google Scholar
• Hauschild A, Agarwala SS, Trefzer U et al. Results of a Phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J. Clin. Oncol.27(17), 2823–2830 (2009).
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med.359(4), 378–390 (2008).
   PubMed Web of Science ®Google Scholar
• Cornu JN, Roupret M, Bensalah K, Oudard S, Patard JJ. Antiangiogenics: new therapeutic standards in metastatic kidney cancer. Prog. Urol.18(Suppl. 4), S69–S76 (2008).
   Google Scholar
• Richter S, Pfister D, Thüer D, Engelmann UH, Heidenreich A. Second-line treatment of progressive metastatic renal cell cancer with temsirolimus following first-line therapy with sunitinib or sorafenib. Onkologie31(Suppl. 4), V684 (2008).
   Google Scholar
• Valcamonico F, Ferrari V, Amoroso V et al. Long-lasting successful cerebral response with sorafenib in advanced renal cell carcinoma. J. Neurooncol.91(1), 47–50 (2009).
   PubMed Web of Science ®Google Scholar
• Hill KL, Lipson AC, Sheehan JM. Brain magnetic resonance imaging changes after sorafenib and sunitinib chemotherapy in patients with advanced renal cell and breast carcinoma. J. Neurosurg.111(3), 497–503 (2009).
   PubMedGoogle Scholar
• Ranze O, Hofmann E, Distelrath A, Hoeffkes HG. Renal cell cancer presented with leptomeningeal carcinomatosis effectively treated with sorafenib. Onkologie30(8–9), 450–451 (2007).
   PubMedGoogle Scholar
• Bellmunt J, Negrier S, Escudier B, Awada A, Aapro M; SIOG Taskforce. The medical treatment of metastatic renal cell cancer in the elderly: position paper of a SIOG Taskforce. Crit. Rev. Oncol. Hematol.69(1), 64–72 (2009).
   PubMed Web of Science ®Google Scholar
• Bhojani N, Jeldres C, Patard JJ et al. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur. Urol.53(5), 917–930 (2008).
   PubMed Web of Science ®Google Scholar
• Ruppin S, Protzel C, Klebingat KJ, Hakenberg OW. Successful sorafenib treatment for metastatic renal cell carcinoma in a case with chronic renal failure. Eur. Urol.55(4), 986–988 (2008).
   PubMedGoogle Scholar
• Escudier B, Eisen T, Stadler WM et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the Phase III treatment approaches in renal cancer global evaluation trial. J. Clin. Oncol.27(20), 3312–3318 (2009).
   PubMed Web of Science ®Google Scholar
• Shepard DR, Rini BR, Garcia J et al. A multicenter prospective trial of sorafenib in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) refractory to prior sunitinib or bevacizumab. J. Clin. Oncol.26(5123), (2008) (Abstract).
   Google Scholar
• Sepulveda J, Maroto P, Andres R et al. Sorafenib as a second-line and sequential therapy for patients with metastatic renal cell carcinoma (mRCC): analysis for safety and activity on sunitinib progressive pts. ASCO Meeting Abstracts26(15 Suppl.) (2008) (Abstract 16100).
   Google Scholar
• Herrmann E, Bierer S, Gerss J, Kopke T, Hertle L, Wulfing C. Prospective comparison of sorafenib and sunitinib for second-line treatment of cytokine-refractory kidney cancer patients. Oncology74(3–4), 216–222 (2008).
   PubMed Web of Science ®Google Scholar
• Escudier B, Ravaud A, Oudard S et al. Phase III randomized trial of everolimus (RAD001) vs placebo in metastatic renal cell carcinoma. Ann. Oncol.19, 720 (2008).
   Google Scholar
• Drabkin HA, Figlin RA, Stadler WM et al. The advanced renal cell carcinoma sorafenib (ARCCS) expanded access trial: Safety and efficacy in patients (pts) with prior bevacizumab (BEV) treatment. American Society of Clinical Oncology Meeting Abstracts25(18 Suppl.), (2007) (Abstract 5041).
   Google Scholar
• Choueiri TK, Brick AJ, McDermott S et al. Treatment and dosing patterns for angiogenesis inhibitor (AIS) therapies in patients with metastatic renal cell carcinoma (MRCC). Ann. Oncol.19(Suppl. 8), 593P (2008).
   Google Scholar
• Zimmermann K, Schmittel A, Steiner U et al. Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib. Oncology76(5), 350–354 (2009).
   PubMed Web of Science ®Google Scholar
• Sablin MP, Negrier S, Ravaud A et al. Sequential sorafenib and sunitinib for renal carcinoma. J. Urol.182, 29–34, (2009).
   PubMed Web of Science ®Google Scholar
• Porta C, Procopio G, Sabbatini R et al. Retrospective analysis of the sequential use of sorafenib and sunitinib in patients with advanced renal cell carcinoma (RCC). Eur. J. Urol.8(Suppl. 4), 183 (2009) (Abstract 252).
   Google Scholar
• Beck J, Bajetta E, Escudier B et al. A large open-label non-comparative Phase III study of the multi-targeted kinase inhibitor sorafenib in European patients with advanced renal cell carcinoma. Eur. J. Cancer5(4 Suppl.), 300 (2007) (Abstract 4506).
   Google Scholar
• Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon α or both for advanced renal-cell carcinoma. N. Engl. J. Med.356, 2271–2281 (2007).
   PubMed Web of Science ®Google Scholar
• Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon α-2a for treatment of metastastic renal cell carcinoma: survival and biomarker analysis. Lancet370, 2103–2111 (2007).
   PubMed Web of Science ®Google Scholar
• Rini BI, Halabi S, Rosenberg JE et al. CALGB 90206: a Phase III trial of bevacizumab plus interferon-α versus interferon-α monotherapy in metastatic renal cell carcinoma. J. Clin. Oncol.26(33), 5422-5428 (2008).
   PubMed Web of Science ®Google Scholar
• Figlin RA, Hutson TE, Tomczak P et al. Overall survival with sunitinib versus interferon (IFN)-α as first-line treatment of metastatic renal cell carcinoma (mRCC). J. Clin. Oncol.26, 5024 (2008).
   Web of Science ®Google Scholar
• Kay A, Motzer RJ, Figlin RA et al. Updated data from a Phase III trial of everolimus (RAD001) versus placebo in patients with metastatic renal cell carcinoma. Presented at: European Association of Urology Annual Congress. Stockholm, Sweden, 17–25 March 2009 (Abstract 257).
   Google Scholar
• Sternberg CN, Szczylik C, Lee E et al. A randomized, double-blind Phase III study of pazopanib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC). Presented at: American Society of Clinical Oncology Annual Meeting. Orlando, FL, USA, 29 May–2 June 2009 (Abstract 5021).
   Google Scholar